文献速递儿童感染儿童消化与营养

轮状病毒疫苗普及后肠道病原谱的变化

Enteropathogen Changes After Rotavirus Vaccine Scale-up.
PubMed 文献 · Pediatrics · 2022-01-01

在秘鲁普及轮状病毒疫苗后,一项纳入1788名5岁以下就诊儿童的病例对照研究显示,诺如病毒GII是胃肠炎的首要归因病原(AF 29.1),轮状病毒、札如病毒、星状病毒、产肠毒素大肠埃希菌和志贺菌亦独立相关。诺如病毒GII阳性病例及6–12月龄病例的病情严重度评分显著更高。

要点

  • 诺如病毒GII是轮状病毒疫苗普及后儿童胃肠炎的首要归因病原。
  • 札如病毒常被忽视,但与诺如病毒一样显著贡献重症疾病负担。
  • 诺如病毒GII阳性及6–12月龄病例的Vesikari和Clark严重度评分更高。

核心结论

  • 轮状病毒疫苗普及后,诺如病毒是儿童胃肠炎首要病原,札如病毒亦贡献显著重症负担。
  • 决策者应考虑多价疫苗策略以覆盖多种杯状病毒。

研究设计与样本

  • 在秘鲁普及轮状病毒疫苗后开展的病例对照研究,纳入1788名5岁以下就诊儿童(伴或不伴胃肠炎)。
  • 检测粪便中5种病毒、19种细菌及寄生虫,计算混合感染校正归因分数(AF)并评估严重度。

主要发现

  • 诺如病毒GII的AF为29.1(95%CI 28.0–32.3),轮状病毒为8.9(95%CI 6.8–9.7)。
  • 札如病毒AF为6.3(95%CI 4.3–7.4),星状病毒为2.8(95%CI 0.0–4.0)。
  • 产肠毒素大肠埃希菌热稳定和/或热不稳定及热稳定株AF为2.4(95%CI 0.6–3.1),志贺菌AF为2.0(95%CI 0.4–2.2)。
  • 可分型轮状病毒病例中最常见为部分异型株G12P[8](54/81,67%)。
  • 诺如病毒GII阳性较阴性病例Vesikari评分12.7 vs 11.8(P<.001)、Clark评分11.7 vs 11.4(P=.016);6–12月龄较其他年龄组Vesikari评分12.7 vs 12.0(P=.0002)、Clark评分12.0 vs 11.4(P=.0016)。

临床怎么用

  • 在轮状病毒疫苗普及地区,儿科医生应重视诺如病毒和札如病毒的检测与重症识别。
  • 6–12月龄婴儿胃肠炎严重度更高,需加强临床评估与干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To inform next steps in pediatric diarrhea burden reduction by understanding the shifting enteropathogen landscape after rotavirus vaccine implementation. METHODS: We conducted a case-control study of 1788 medically attended children younger than 5 years, with and without gastroenteritis, after universal rotavirus vaccine implementation in Peru. We tested case and control stools for 5 viruses, 19 bacteria, and parasites; calculated coinfection-adjusted attributable fractions (AFs) to determine pathogen-specific burdens; and evaluated pathogen-specific gastroenteritis severity using Clark and Vesikari scales. RESULTS: Six pathogens were independently positively associated with gastroenteritis: norovirus genogroup II (GII) (AF 29.1, 95% confidence interval [CI]: 28.0-32.3), rotavirus (AF 8.9, 95% CI: 6.8-9.7), sapovirus (AF 6.3, 95% CI: 4.3-7.4), astrovirus (AF 2.8, 95% CI: 0.0-4.0); enterotoxigenic Escherichia coli heat stable and/or heat labile and heat stable (AF 2.4, 95% CI: 0.6-3.1), and Shigella spp. (AF 2.0, 95% CI: 0.4-2.2). Among typeable rotavirus cases, we most frequently identified partially heterotypic strain G12P[8] (54 of 81, 67%). Mean severity was significantly higher for norovirus GII-positive cases relative to norovirus GII-negative cases (Vesikari [12.7 vs 11.8; P < .001] and Clark [11.7 vs 11.4; P = .016]), and cases in the 6- to 12-month age range relative to cases in other age groups (Vesikari [12.7 vs 12.0; P = .0002] and Clark [12.0 vs 11.4; P = .0016]). CONCLUSIONS: Norovirus is well recognized as the leading cause of pediatric gastroenteritis in settings with universal rotavirus vaccination. However, sapovirus is often overlooked. Both norovirus and sapovirus contribute significantly to the severe pediatric disease burden in this setting. Decision-makers should consider multivalent vaccine acquisition strategies to target multiple caliciviruses in similar countries after successful rotavirus vaccine implementation.

来源:Pediatrics,查看原文。版权归原作者所有。

引用

  1. Ballard SB, Requena D, Mayta H, et al. Enteropathogen Changes After Rotavirus Vaccine Scale-up. Pediatrics. 2022. PMID: 34918158. doi:10.1542/peds.2020-049884

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。